ArticleOncotarget2012

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.

Guillaume Robert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.